Week 48 Resistance Analyses of the Once-daily, Single-tablet Regimen (STR) Darunavir/cobicistat/emtricitabine/tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

Erkki Lathouwers,Eric Y. Wong,Kimberley Brown,Bryan P. Baugh,Anne Ghys,John Jezorwski,El Ghazi Mohsine,Erika Van Landuyt,Magda Opsomer,Sandra De Meyer

Week 48 Resistance Analyses of the Once-daily, Single-tablet Regimen (STR) Darunavir/cobicistat/emtricitabine/tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

2019

Erkki Lathouwers
Eric Y. Wong
Kimberley Brown
Bryan P. Baugh
Anne Ghys
John Jezorwski
El Ghazi Mohsine
Erika Van Landuyt
Magda Opsomer
Sandra De Meyer

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials. AMBER (NCT02431247; treatment-naive-adults) and EMERALD (NCT022...

Keywords:

Darunavir
Virology
Darunavir/Cobicistat
Regimen
Tenofovir alafenamide
Emtricitabine tenofovir alafenamide
Cobicistat
Biology
Emtricitabine
human immunodeficiency virus
single tablet regimen
once daily

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations